EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer

Share :
Published: 3 Jun 2012
Views: 18990
Rating:
Save
Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

Dr Kimberly Blackwell interviewed by Professor David Miles, Mount Vernon Hospital, London, UK, about the EMILIA trial at the ASCO 2012 Annual Meeting in Chicago, June 2012.

 

The EMILIA trial is a phase III randomised study of the investigational agent trastuzumab emtansine (T-DM1) vs. standard therapy using capecitabine and lapatinib.

 

Dr Blackwell and her team found significant and clinically meaningful improvement in progression-free survival with T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab.